OSI Systems, NVE, Clene, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies that research, develop or commercialize materials and devices at the nanoscale (one billionth of a meter). Investors buy these stocks to gain exposure to firms aiming to revolutionize sectors like electronics, medicine and energy through breakthroughs in molecular‐scale engineering. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
NASDAQ:OSIS traded down $2.41 on Thursday, reaching $236.64. 68,708 shares of the stock traded hands, compared to its average volume of 197,878. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of 30.46, a price-to-earnings-growth ratio of 1.81 and a beta of 1.28. OSI Systems has a 1-year low of $129.18 and a 1-year high of $241.64. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. The company's 50 day moving average is $211.89 and its 200-day moving average is $194.97.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NVEC traded down $1.17 during mid-day trading on Thursday, reaching $72.21. 37,842 shares of the stock were exchanged, compared to its average volume of 26,789. The stock has a market capitalization of $349.28 million, a PE ratio of 23.29 and a beta of 1.15. The company has a 50 day moving average price of $64.83 and a two-hundred day moving average price of $70.67. NVE has a 1 year low of $51.50 and a 1 year high of $89.98.
Read Our Latest Research Report on NVEC
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of NASDAQ CLNN traded down $0.10 during mid-day trading on Thursday, reaching $4.10. 52,024 shares of the company's stock were exchanged, compared to its average volume of 88,140. Clene has a 52 week low of $2.28 and a 52 week high of $8.60. The firm has a 50-day moving average price of $3.05 and a two-hundred day moving average price of $3.99. The firm has a market capitalization of $36.83 million, a price-to-earnings ratio of -0.78 and a beta of 0.49.
Read Our Latest Research Report on CLNN
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Biodexa Pharmaceuticals stock traded down $0.02 during midday trading on Thursday, reaching $1.11. The stock had a trading volume of 71,485 shares, compared to its average volume of 851,396. Biodexa Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $41.50. The firm's 50-day moving average price is $1.35 and its 200 day moving average price is $2.93.
Read Our Latest Research Report on BDRX
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Virpax Pharmaceuticals stock traded up $0.00 during midday trading on Thursday, reaching $0.26. The stock had a trading volume of 906 shares, compared to its average volume of 201,748. The firm's 50-day moving average price is $0.25 and its 200 day moving average price is $4.64. Virpax Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $84.75.
Read Our Latest Research Report on VRPX
Clene (CLNNW)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of CLNNW traded up $0.00 during midday trading on Thursday, hitting $0.04. 118 shares of the company traded hands, compared to its average volume of 10,320. The stock has a 50-day moving average of $0.03 and a 200-day moving average of $0.04. Clene has a one year low of $0.02 and a one year high of $0.08.
Read Our Latest Research Report on CLNNW
Read More
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
